Stockscreener 앱 받기
11.82
4.14%
-0.51
시간 외 거래:
12.00
0.18
+1.52%
전일 마감가:
$12.33
열려 있는:
$11.96
하루 거래량:
120.17K
Relative Volume:
0.78
시가총액:
$4.00B
수익:
$804.63M
순이익/손실:
$-7.13M
주가수익비율:
-560.19
EPS:
-0.0211
순현금흐름:
$-73.42M
1주 성능:
+2.60%
1개월 성능:
+7.26%
6개월 성능:
+80.73%
1년 성능:
+7.55%
1일 변동 폭
$11.75
$11.99
1주일 범위
$11.67
$12.33
52주 변동 폭
$6.28
$12.60
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Compare TLX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
11.82 | 4.06B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 개시 | H.C. Wainwright | Buy |
| 2025-06-05 | 개시 | Wedbush | Outperform |
| 2024-11-15 | 개시 | UBS | Buy |
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Telix Pharmaceuticals (ASX:TLX): Radiopharmaceutical Innovator Pauses in a Rising Sector - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
Telix gets FDA alignment on prostate cancer trial expansion to US - Investing.com
Telix Pharmaceuticals Limited Sponsored ADR Actuals & Estimates (NASDAQ:TLX) - TradingView
Telix webinar spotlights glioblastoma care and theranostics next week - Stock Titan
ASX Healthcare Sector Rally: CSL, ResMed and Telix Advance on Broad Market Strength - Kalkine
AI-enhanced cancer scans: Telix and United Imaging team up on theranostics - Stock Titan
Prostate cancer trial: Telix therapy shows acceptable safety in combo treatment - stocktitan.net
Telix CEO lines up back-to-back investor talks in Chicago and New York - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Stock Price and Quote - Finviz
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals Ltd stock (AU000000TLX2): FDA filing advances - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Prostate cancer imaging tie-up aims to cut incontinence, impotence risks - Stock Titan
Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision? - Kalkine
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
Kidney cancer scan showed 98% positive predictive value in analysis - Stock Titan
Europe begins 210-day review of Telix brain cancer imaging candidate - Stock Titan
Telix reports dosimetry data for prostate cancer therapy candidate - Investing.com
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
TLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
Telix’s Phase 3 prostate cancer study gets a late-breaking ASCO slot - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
First radiopharmaceutical enters Phase 3 for recurrent brain cancer - Stock Titan
Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum - International Business Times Australia
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
Brain cancer imaging agent moves toward FDA decision by Sept. 11 - Stock Titan
Former Pfizer and Stryker leaders join Telix board expansion - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on revenue growth - Investing.com
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):